Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 233

1.

The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Nutter B, Jain A, Atreja A, Zimmerman RS.

Diabet Med. 2012 Aug;29(8):1029-35. doi: 10.1111/j.1464-5491.2012.03577.x.

PMID:
22248043
2.

Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.

Diabetes Obes Metab. 2012 Sep;14(9):803-9. doi: 10.1111/j.1463-1326.2012.01604.x. Epub 2012 Apr 29.

PMID:
22486923
3.

The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.

Diabetes Care. 2010 Jun;33(6):1224-9. doi: 10.2337/dc10-0017. Epub 2010 Mar 9.

4.

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.

Bowker SL, Majumdar SR, Veugelers P, Johnson JA.

Diabetes Care. 2006 Feb;29(2):254-8.

PMID:
16443869
5.

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin.

Evans JM, Ogston SA, Emslie-Smith A, Morris AD.

Diabetologia. 2006 May;49(5):930-6. Epub 2006 Mar 9.

PMID:
16525843
6.

Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention--a retrospective nationwide cohort study.

Jørgensen CH, Gislason GH, Andersson C, Ahlehoff O, Charlot M, Schramm TK, Vaag A, Abildstrøm SZ, Torp-Pedersen C, Hansen PR.

Cardiovasc Diabetol. 2010 Sep 16;9:54. doi: 10.1186/1475-2840-9-54.

7.

Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy.

Wheeler S, Moore K, Forsberg CW, Riley K, Floyd JS, Smith NL, Boyko EJ.

Diabetologia. 2013 Sep;56(9):1934-43. doi: 10.1007/s00125-013-2958-1. Epub 2013 Jun 25.

PMID:
23797633
9.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
10.

Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up.

Fisman EZ, Tenenbaum A, Benderly M, Goldbourt U, Behar S, Motro M.

Cardiology. 1999;91(3):195-202.

PMID:
10516414
11.

Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure.

Andersson C, Gislason GH, Jørgensen CH, Hansen PR, Vaag A, Sørensen R, Mérie C, Olesen JB, Weeke P, Schmiegelow M, Norgaard ML, Køber L, Torp-Pedersen C.

Diabetes Res Clin Pract. 2011 Oct;94(1):119-25. doi: 10.1016/j.diabres.2011.07.011. Epub 2011 Aug 9.

PMID:
21831467
12.

Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.

Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, Fosbøl EL, Køber L, Norgaard ML, Madsen M, Hansen PR, Torp-Pedersen C.

Eur Heart J. 2011 Aug;32(15):1900-8. doi: 10.1093/eurheartj/ehr077. Epub 2011 Apr 6. Erratum in: Eur Heart J. 2012 May;33(10):1183.

PMID:
21471135
13.

Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.

Mogensen UM, Andersson C, Fosbøl EL, Schramm TK, Vaag A, Scheller NM, Torp-Pedersen C, Gislason G, Køber L.

Diabetes Res Clin Pract. 2015 Jan;107(1):104-12. doi: 10.1016/j.diabres.2014.09.047. Epub 2014 Oct 7.

PMID:
25458330
14.

Coronary heart disease outcomes in patients receiving antidiabetic agents.

McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM.

Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):711-25.

PMID:
17551989
15.

Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients.

Abbink EJ, Pickkers P, Jansen van Rosendaal A, Lutterman JA, Tack CJ, Russel FG, Smits P.

Diabet Med. 2002 Feb;19(2):136-43.

PMID:
11874430
16.

Hypoglycemia in hospitalized patients treated with sulfonylureas.

Deusenberry CM, Coley KC, Korytkowski MT, Donihi AC.

Pharmacotherapy. 2012 Jul;32(7):613-7. doi: 10.1002/j.1875-9114.2011.01088.x. Epub 2012 May 8.

PMID:
22570146
18.

All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides.

Mannucci E, Monami M, Masotti G, Marchionni N.

Diabetes Metab Res Rev. 2004 Jan-Feb;20(1):44-7.

PMID:
14737744
19.

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.

Acta Diabetol. 2009 Jun;46(2):145-54. doi: 10.1007/s00592-008-0090-3. Epub 2009 Feb 5.

PMID:
19194648
20.

Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.

Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA.

CMAJ. 2006 Jan 17;174(2):169-74.

Supplemental Content

Support Center